Skip to Main content Skip to Navigation
Journal articles

Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens

Abstract : This study evaluated the midterm delivery of doxorubicin in liver specimens from patients (N = 4) with hepatocellular carcinoma treated with drug-eluting embolic (DEE) transarterial chemoembolization. The patients had surgical resection 57, 79, 80 and 105 days after doxorubicin DEE chemoembolization. Doxorubicin concentrations inside embolic particles and in surrounding tissues were assessed by infrared microspectroscopy and microspectrofluorimetry, respectively. Embolic particles still contained doxorubicin and provided sustained drug delivery within targeted tissues 80 days after chemoembolization. Doxorubicin was undetectable after 105 days. In addition, aggregation of embolic particles inside vessel lumina was associated with slower doxorubicin elution and higher tissue concentrations when the number of aggregated embolic particles increased.
Complete list of metadatas

https://hal.univ-reims.fr/hal-02929433
Contributor : Brigitte Perron <>
Submitted on : Thursday, September 3, 2020 - 2:23:29 PM
Last modification on : Friday, September 4, 2020 - 8:47:37 AM

Identifiers

Collections

Citation

Hadrien D’inca, Olivier Piot, Marie-Danièle Diebold, Tullio Piardi, Claude Marcus, et al.. Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. JVIR: Journal of Vascular and Interventional Radiology, Elsevier, 2017, 28 (6), pp.804-810. ⟨10.1016/j.jvir.2017.01.018⟩. ⟨hal-02929433⟩

Share

Metrics

Record views

16